Richard N Upton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2392652/publications.pdf

Version: 2024-02-01

201385 197535 2,847 113 27 49 citations g-index h-index papers 120 120 120 2696 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 387-402.	0.6	1
2	Mucoadhesive Buccal Film of Estradiol for Hormonal Replacement Therapy: Development and In-Vivo Performance Prediction. Pharmaceutics, 2022, 14, 542.	2.0	11
3	Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer's Disease, in Serum and Tissue of Sprague Dawley Rats. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 235-248.	0.6	1
4	Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. European Journal of Clinical Pharmacology, 2021, 77, 1357-1368.	0.8	2
5	3D Printing of Thermo-Sensitive Drugs. Pharmaceutics, 2021, 13, 1524.	2.0	28
6	Population pharmacokineticâ€pharmacodynamic modelling of liquid and controlledâ€release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 263-276.	1.2	13
7	Effects of Vasopressors on Cerebral Circulation and Oxygenation: A Narrative Review of Pharmacodynamics in Health and Traumatic Brain Injury. Journal of Neurosurgical Anesthesiology, 2020, 32, 18-28.	0.6	20
8	<p>Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study</p> . Drug Design, Development and Therapy, 2020, Volume 14, 961-967.	2.0	2
9	Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis. AAPS Journal, 2020, 22, 32.	2.2	2
10	Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimer's Disease, in Sprague Dawley Rats. Current Drug Metabolism, 2020, 21, 235-244.	0.7	7
11	Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. Journal of Pharmacy and Pharmacology, 2019, 71, 1635-1644.	1.2	7
12	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology, 2019, 84, 1073-1087.	1.1	8
13	Population pharmacokinetics of lenalidomide in patients with Bâ€cell malignancies. British Journal of Clinical Pharmacology, 2019, 85, 924-934.	1.1	8
14	Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 201-215.	0.6	9
15	Population in vitro–in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 181-197.	0.8	5
16	Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers. Pain Medicine, 2018, 19, 1988-1996.	0.9	11
17	Transfer of rosuvastatin into breast milk: liquid chromatography–mass spectrometry methodology and clinical recommendations. Drug Design, Development and Therapy, 2018, Volume 12, 3645-3651.	2.0	9
18	Estimation of Atenolol Transfer Into Milk and Infant Exposure During Its Use in Lactating Women. Journal of Human Lactation, 2018, 34, 592-599.	0.8	7

#	Article	IF	CITATIONS
19	Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming. AAPS Journal, 2018, 20, 76.	2.2	17
20	Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	7
21	Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 233-244.	0.8	6
22	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. AAPS Journal, 2017, 19, 1136-1147.	2.2	26
23	Food, gastrointestinal pH, and models of oral drug absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 234-248.	2.0	197
24	Intracellular CD3 ⁺ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration. Drug Metabolism and Disposition, 2017, 45, 8-16.	1.7	9
25	A modelâ€based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 2016, 81, 1046-1057.	1.1	1
26	Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Pharmaceutical Research, 2016, 33, 1782-1794.	1.7	27
27	A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption—Part I: Gastrointestinal pH. AAPS Journal, 2016, 18, 1309-1321.	2.2	90
28	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2016, 81, 113-123.	1.1	19
29	An introduction to physiologicallyâ€based pharmacokinetic models. Paediatric Anaesthesia, 2016, 26, 1036-1046.	0.6	29
30	A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorptionâ€"Part II: Gastrointestinal Transit Time. AAPS Journal, 2016, 18, 1322-1333.	2.2	58
31	Modelling the PKPD of oxycodone in experimental pain â€" Impact of opioid receptor polymorphisms. European Journal of Pharmaceutical Sciences, 2016, 86, 41-49.	1.9	3
32	Altering blood flow does not reveal differences between nitrogen and helium kinetics in brain or in skeletal miracle in sheep. Journal of Applied Physiology, 2015, 118, 586-594.	1.2	4
33	ADVAN-style analytical solutions for common pharmacokinetic models. Journal of Pharmacological and Toxicological Methods, 2015, 73, 42-48.	0.3	5
34	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British Journal of Clinical Pharmacology, 2015, 79, 777-788.	1.1	4
35	Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States. Antimicrobial Agents and Chemotherapy, 2015, 59, 5681-5696.	1.4	80
36	Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. Journal of Antimicrobial Chemotherapy, 2015, 70, 868-876.	1.3	14

3

#	Article	IF	CITATIONS
37	Pharmacodynamic Modelling of Placebo and Buprenorphine Effects on Eventâ€Related Potentials in Experimental Pain. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 343-351.	1.2	4
38	Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 2014, 11, 449-461.	0.8	6
39	Pharmacokinetic–Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 257-267.	1.2	7
40	Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside. AAPS Journal, 2014, 16, 925-937.	2.2	41
41	Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. BMC Anesthesiology, 2014, 14, 33.	0.7	6
42	Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2013, 71, 209-218.	1.1	30
43	A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 561-576.	0.8	11
44	The influence of drug sorption on pharmacokinetic studies of chlormethiazole and lignocaine. Journal of Pharmacy and Pharmacology, 2011, 39, 485-487.	1.2	10
45	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 274-284.	1.2	36
46	Advances in analgesia in the older patient. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2011, 25, 367-378.	1.7	28
47	Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. European Journal of Anaesthesiology, 2010, 27, 241-246.	0.7	20
48	The Performance of Compartmental and Physiologically Based Recirculatory Pharmacokinetic Models for Propofol. Anesthesia and Analgesia, 2010, 111, 368-379.	1.1	108
49	Development and Validation of a Recirculatory Physiological Model of the Myocardial Concentrations of Lignocaine after Intravenous Administration in Sheep. Journal of Pharmacy and Pharmacology, 2010, 52, 181-189.	1.2	8
50	Inhibition of Morphine Metabolism by Ketamine. Drug Metabolism and Disposition, 2010, 38, 728-731.	1.7	27
51	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clinical Pharmacokinetics, 2010, 49, 817-827.	1.6	24
52	Translational pain research: Evaluating analgesic effect in experimental visceral pain models. World Journal of Gastroenterology, 2009, 15, 177.	1.4	14
53	Pharmacokinetic–Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 94-101.	1.2	26
54	PHARMACOKINETICS AND PHARMACODYNAMICS OF INDOMETHACIN: EFFECTS ON CEREBRAL BLOOD FLOW IN ANAESTHETIZED SHEEP. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 317-323.	0.9	12

#	Article	IF	CITATIONS
55	Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. Journal of Pharmacological and Toxicological Methods, 2008, 58, 198-205.	0.3	73
56	Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clinical Therapeutics, 2008, 30, 469-481.	1.1	106
57	Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Annals of Pharmacotherapy, 2008, 42, 1380-1387.	0.9	80
58	Pharmacokineticâ€Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. Journal of Clinical Pharmacology, 2008, 48, 619-631.	1.0	54
59	Acute pain management in the elderly patient. , 2008, , 504-525.		o
60	Reduced Intrathoracic Blood Volume and Left and Right Ventricular Dimensions in Patients With Severe Emphysema. Chest, 2007, 131, 1050-1057.	0.4	134
61	A Comparison of Pharmacokinetic/Pharmacodynamic versus Mass-Balance Measurement of Brain Concentrations of Intravenous Anesthetics in Sheep. Anesthesia and Analgesia, 2007, 104, 1440-1446.	1.1	19
62	An audit of the safety and effectiveness of an alfentanil:morphine mixture in the postanaesthesia care unit. Acute Pain, 2007, 9, 13-19.	0.1	2
63	CEREBRAL UPTAKE OF DRUGS IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 695-701.	0.9	47
64	A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. British Journal of Clinical Pharmacology, 2007, 64, 335-345.	1.1	30
65	Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology, 2007, 63, 1153-1159.	0.8	19
66	The Effects of Indomethacin on Intracranial Pressure and Cerebral Hemodynamics During Isoflurane or Propofol Anesthesia in Sheep with Intracranial Hypertension. Anesthesia and Analgesia, 2006, 102, 1823-1829.	1.1	6
67	Blood-brain equilibration kinetics of levo- $\hat{l}\pm$ -acetyl-methadol using a chronically instrumented sheep preparation. British Journal of Pharmacology, 2006, 147, 209-217.	2.7	3
68	Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 2006, 95, 1666-1676.	1.6	24
69	A Physiologically Based, Recirculatory Model of the Kinetics and Dynamics of Propofol in Man. Anesthesiology, 2005, 103, 344-352.	1.3	63
70	BRAIN PHARMACOKINETICS OF LIGNOCAINE BEFORE and FOLLOWING INTRAVENOUS PERFLUOROCARBON EMULSION INFUSION IN SHEEP. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 367-371.	0.9	1
71	Perfusion-diffusion compartmental models describe cerebral helium kinetics at high and low cerebral blood flows in sheep. Journal of Physiology, 2005, 563, 529-539.	1.3	12
72	The Acute Disposition of (R)- and (S)-Methadone in Brain and Lung of Sheep. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 547-570.	0.8	7

#	Article	IF	Citations
73	Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs - method development and application to magnesium in sheep. BMC Pharmacology, 2005, 5, 5.	0.4	23
74	Calculating the hybrid (macro) rate constants of a three-compartment mamillary pharmacokinetic model from known micro-rate constants. Journal of Pharmacological and Toxicological Methods, 2004, 49, 65-68.	0.3	20
75	The effect of infusions of adrenaline, noradrenaline and dopamine on cerebral autoregulation under propofol anaesthesia in an ovine model. Intensive Care Medicine, 2003, 29, 817-824.	3.9	21
76	The Effect of Hypoxic Hypoxia on the Systemic and Myocardial Pharmacokinetics and Dynamics of Lidocaine in Sheep. Journal of Pharmaceutical Sciences, 2003, 92, 180-189.	1.6	3
77	The Contribution of the Coronary Concentrations of Propofol to Its Cardiovascular Effects in Anesthetized Sheep. Anesthesia and Analgesia, 2003, 96, 1589-1597.	1.1	11
78	Determinants of drug onset. Current Opinion in Anaesthesiology, 2002, 15, 409-414.	0.9	5
79	A quantitative alternative to the hysteresis plot for measurement of drug transit time. Journal of Pharmacological and Toxicological Methods, 2002, 47, 45-51.	0.3	1
80	Propofol use in head-injury patients. Lancet, The, 2001, 357, 1709.	6.3	7
81	Epinephrine, norepinephrine and dopamine infusions decrease propofol concentrations during continuous propofol infusion in an ovine model. Intensive Care Medicine, 2001, 27, 276-282.	3.9	7 9
82	Increased Cerebral Blood Flow And Cardiac Output Following Cerebral Arterial Air Embolism In Sheep. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 868-872.	0.9	10
83	In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28, 129-153.	0.8	7
84	Relationships between steady state blood concentrations and cardiac output during intravenous infusions. Biopharmaceutics and Drug Disposition, 2000, 21, 69-76.	1.1	17
85	Cardiac Output is a Determinant of the Initial Concentrations of Propofol After Short-Infusion Administration. Anesthesia and Analgesia, 1999, 89, 545.	1.1	68
86	Cardiac Output is a Determinant of the Initial Concentrations of Propofol After Short-Infusion Administration. Anesthesia and Analgesia, 1999, 89, 545.	1.1	119
87	A compartmental analysis of the pharmacokinetics of propofol in sheep. Journal of Pharmacokinetics and Pharmacodynamics, 1999, 27, 329-338.	0.6	13
88	Diffusion-limited, but not perfusion-limited, compartmental models describe cerebral nitrous oxide kinetics at high and low cerebral blood flows. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 649-672.	0.6	20
89	The Effect of Rate of Administration on Brain Concentrations of Propofol in Sheep. Anesthesia and Analgesia, 1998, 86, 1301-1306.	1.1	10
90	The Influence of the Bolus Injection Rate of Propofol on Its Cardiovascular Effects and Peak Blood Concentrations in Sheep. Anesthesia and Analgesia, 1998, 86, 1109-1115.	1.1	10

#	Article	IF	Citations
91	The Effect of Rate of Administration on Brain Concentrations of Propofol in Sheep. Anesthesia and Analgesia, 1998, 86, 1301-1306.	1.1	27
92	The Influence of the Bolus Injection Rate of Propofol on Its Cardiovascular Effects and Peak Blood Concentrations in Sheep. Anesthesia and Analgesia, 1998, 86, 1109-1115.	1.1	25
93	Pharmacokinetic Optimisation of Opioid Treatment in Acute Pain Therapy. Clinical Pharmacokinetics, 1997, 33, 225-244.	1.6	102
94	Drugs and brain death. Medical Journal of Australia, 1996, 165, 394-398.	0.8	8
95	In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 1-18.	0.6	14
96	A Descriptive Tool to Characterize Nonlinear Kinetics, with Applications to Meperidine and Lidocaine. Journal of Pharmaceutical Sciences, 1996, 85, 362-368.	1.6	4
97	Myocardial Pharmacokinetics of Thiopental in Sheep after Short-Term Administration: Relationship to Thiopental-Induced Reductions in Myocardial Contractility. Journal of Pharmaceutical Sciences, 1996, 85, 863-867.	1.6	9
98	RELATIONSHIPS BETWEEN BLOOD DRUG CONCENTRATIONS AND CEREBRAL EFFECTS. Clinical and Experimental Pharmacology and Physiology, 1996, 23, s52-s53.	0.9	0
99	A method for frequent measurement of sedation and analgesia in sheep using the response to a ramped electrical stimulus. Journal of Pharmacological and Toxicological Methods, 1995, 33, 17-22.	0.3	30
100	An analysis of errors arising from the direct use of mass balance principles to describe regional drug uptake and elution. Journal of Pharmacokinetics and Pharmacodynamics, 1994, 22, 309-321.	0.6	10
101	An Ultrasonic Doppler Venous Outflow Method for the Continuous Measurement of Cerebral Blood Flow in Conscious Sheep. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 680-688.	2.4	53
102	The Hemodynamic Effects of Intravenous Bolus Doses of Meperidine in Conscious Sheep. Anesthesia and Analgesia, 1994, 78, 442???449.	1.1	13
103	The Pharmacokinetics of Meperidine in the Myocardium of Conscious Sheep. Anesthesia and Analgesia, 1994, 79, 987???992.	1.1	3
104	An estimate of the rate of direct drug diffusion from the surface of heart and kidneyâ€"implications for their representation as compartments. Biopharmaceutics and Drug Disposition, 1993, 14, 647-658.	1.1	2
105	Regional pharmacokinetics III. Modelling methods. Biopharmaceutics and Drug Disposition, 1991, 12, 1-15.	1.1	6
106	Uptake and Elution of Chlormethiazole, Meperidine, and Minaxolone in the Hindquarters of Sheep: Implications for Clearance Calculations. Journal of Pharmaceutical Sciences, 1991, 80, 108-112.	1.6	8
107	An assessment of methods for sampling blood to characterize rapidly changing blood drug concentrations. Journal of Pharmaceutical Sciences, 1991, 80, 847-851.	1.6	11
108	Pharmacokinetics and pharmacodynamics in the critically ill. Bailliere's Clinical Anaesthesiology, 1990, 4, 271-303.	0.2	8

#	Article	IF	CITATIONS
109	Regional pharmacokinetics I. physiological and physicochemical basis. Biopharmaceutics and Drug Disposition, 1990, 11, 647-662.	1.1	18
110	Regional pharmacokinetics II. Experimental methods. Biopharmaceutics and Drug Disposition, 1990, 11, 741-752.	1.1	6
111	Hemodynamic and Central Nervous System Effects of Intravenous Bolus Doses of Lidocaine, Bupivacaine, and Ropivacaine in Sheep. Anesthesia and Analgesia, 1989, 69, 291???299.	1.1	121
112	The use of mass balance principles to describe regional drug distribution and elimination. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 13-29.	0.6	50
113	The uptake and elution of lignocaine and procainamide in the hindquarters of the sheep described using mass balance principles. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 31-40.	0.6	27